Plain-English translation of NCT06501378 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for people with advanced non-small cell lung cancer that has spread to the brain. The study combines brain radiation therapy with PD-1/PD-L1 inhibitors (a type of immunotherapy that helps your immune system fight cancer) and chemotherapy. Researchers believe this combination approach may work better together than any single treatment alone.
Most people with advanced lung cancer and brain tumors have had poor survival rates with traditional treatments. While the new treatment approach shows promise, there is still a need for more research to confirm that combining brain radiation with this medication is both safe and effective, especially in patients whose cancer doesn't have certain genetic mutations.
You likely qualify if…
You likely don't qualify if…
You would receive a combination of treatments: stereotactic or whole-brain radiation therapy to target brain tumors, along with intravenous chemotherapy and immunotherapy infusions. You would have regular imaging scans (brain MRI) and blood tests to monitor how you're responding to treatment. The study involves close follow-up visits with your medical team to watch for any side effects and track how well the treatment is working.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China